203258-60-0 Usage
Description
BROSTALLICIN is a synthetic, cyclic enediyne antitumor antibiotic derived from the bacterium Streptomyces brostallicus. It is characterized by its potent cytotoxic and antitumor activity, making it a promising candidate for the treatment of various types of cancer. BROSTALLICIN operates by inducing DNA damage and apoptosis in cancer cells, which results in their death. Its unique chemical structure and mechanism of action also contribute to its value in understanding the biology of cancer and in the development of new anticancer drugs.
Uses
Used in Oncology:
BROSTALLICIN is used as an antitumor agent for its ability to induce DNA damage and apoptosis in cancer cells, leading to their death. This makes it a potential treatment for various types of cancer.
Used in Clinical Trials:
BROSTALLICIN is used as a subject of investigation in clinical trials for the treatment of solid tumors, including lung, breast, and ovarian cancers. These trials aim to evaluate its safety, efficacy, and potential as an anticancer drug.
Used in Cancer Research:
Due to its unique chemical structure and mechanism of action, BROSTALLICIN is used as a valuable tool in cancer research. It aids in understanding the biology of cancer and contributes to the development of new anticancer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 203258-60-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,2,5 and 8 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 203258-60:
(8*2)+(7*0)+(6*3)+(5*2)+(4*5)+(3*8)+(2*6)+(1*0)=100
100 % 10 = 0
So 203258-60-0 is a valid CAS Registry Number.
203258-60-0Relevant articles and documents
Cytotoxic α-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety
Cozzi, Paolo,Beria, Italo,Caldarelli, Marina,Geroni, Cristina,Mongelli, Nicola,Pennella, Giulia
, p. 1273 - 1276 (2000)
The design, synthesis, in vitro and in vivo activities of novel α-bromoacrylic derivatives of distamycin A, modified at the amidino moiety by the replacement with basic or non-basic groups are reported. In spite of the relevance of these modifications of distamycin frame, the new derivatives are potent cytotoxics. The presence of the amidino moiety, is, therefore, not an absolute requirement for the activity. In particular due to a favorable myelotoxicity/cytotoxicity ratio, guanidino derivative PNU 166196 was selected for clinical development. (C) 2000 Elsevier Science Ltd. All rights reserved.
Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
-
, (2008/06/13)
Compounds which are α-halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable salt thereof; are cytotoxic agents particularly effective in the treatment of tumors over expressing GSH/GSTs system and which are poorly responsive or even resistant to conventional antitumor therapies.